Email Alert | RSS    帮助

中国防痨杂志 ›› 2005, Vol. 27 ›› Issue (6): 358-359.

• 论著 • 上一篇    下一篇

微卡辅助治疗菌阳肺结核的近期效果观察

李月龙;矫庆辉;门文若;刘建木;   

  1. 吉林省吉林市结核病防治研究所 吉林 132011;
  • 出版日期:2005-06-10 发布日期:2005-11-03

Observation on curative effect of positive bacteria pulmonary tuberculosis treated with chemotherapy and vaccae

Li Yuelong,Jiao Qing hui,Men Wenruo,et al.   

  1. JiLin City Tuberculosis Institute,JiLin 132011 China
  • Online:2005-06-10 Published:2005-11-03

摘要: 目的 评价微卡(Vaccae)治疗菌阳肺结核的临床疗效。方法 169例初治菌阳肺结核和90例复治菌阳肺结核,随机分为A、B、C、D组,A组(85例)、B组(84例)采用2HRZS(E)/4HR方案;C组(45例)、D组(45例)采用3HRZA(E)/6HR方案;A、C 2组加用微卡。观察治疗后肺部病灶吸收、痰菌阴转情况。结果 3个月末痰菌阴转率:A、B组分别为80.0%和65.5%,C、D组分别为71.1%和62.2%;疗程结束时痰菌阴转率A、B组分别为97.6%和84.5%,C、D组分别为95.6%和77.8%。疗程结束时胸部X线显著吸收率:A、B组分别为90.6%和75.0%,C、D组分别为82.2%和60.0%。空洞闭合:A、B、C、D组分别为85.9%、64.3%、77.8%、57.7%。结论 微卡辅助治疗菌阳肺结核能提高痰菌阴转率,促进肺部病灶吸收,提高免疫细胞活性,是一种较好的免疫制剂,建议推广使用。

关键词: 结核,肺/药物疗法, 微卡

Abstract: Objective To evaluate the clinical curative effect of bacteriological positive pulmonary tuberculosis. Methods 169 primary and 90 re-treated bacteriological positive pulmonary tuberculosis cases were divided into groups A,B,C and D randomy.Group A(85 cases) and group B(84 cases) were treated with 2HRZS(E)/4HR;Group C(45 Cases) and group D(45 cases) were treated with 3HRZA(E)/6HR.Vaccae was added in Group A and Group C.Then observe the foci absorption and the sputum negative conversion. Results At the end of 3 months of treatment,the sputum negative conversion rate of groups A,B,C and D was 80.0%,65.5%,71.1% and 62.2% respectively.At the end of treatment,the sputum negative conversion rate of groups A,B,C and D was 97.6%,84.5%,95.6%and 77.8%;the foci absorption rate to groups A、B、C、D Was separately 90.6%,75.0%,82.2%and 60.0% respectively;Cavity close up rate was 85.9%,64.3%,77.8% and 57.7% respectively. Conclusion Vaccae can improve the sputum negative conversion rate,accelerate the foci absorption and improve the vitality of immune cells.It is a good immunity injection to be recommended for expansion usage.

Key words: Tuberculosis,pulmonary/therapy, Vaccae